BTG's DC bead for liver cancer delayed in Japan
This article was originally published in Scrip
Executive Summary
BTG says that a submission for its DC Bead product for hepatocellular carcinoma has been accepted for review in China but said that Japanese regulators have requested additional safety data on the product.